OSLO—Norway will delay its decision on whether to resume the use of AstraZeneca’s COVID-19 vaccine by up to three weeks, the Norwegian Institute of Public Health (FHI) said on Friday.
Authorities on March 11 suspended the rollout of the vaccine after a small number of younger inoculated people were hospitalized for a combination of blood clots, bleeding, and a low count of platelets, some of whom later died.
